Description: <b>Bicalutamide</b> brand name Casodex. An antiandrogen medication that is primarily used to treat prostate cancer.<br>
<p><b>Bicalutamide</b> — Bicalutamide is a synthetic, orally active nonsteroidal antiandrogen that functions primarily as an androgen receptor antagonist. Its formal classification is a first-generation androgen receptor inhibitor drug used mainly in prostate cancer, most commonly in combination with a luteinizing hormone-releasing hormone agonist. Standard abbreviations include BIC and the brand name Casodex. It is a racemate, but most antiandrogenic activity resides in the R-enantiomer. Clinically, its current established role is older combined androgen blockade rather than the more potent modern AR-pathway agents used in many contemporary prostate cancer settings.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Competitive androgen receptor antagonism with disruption of AR transcriptional signaling</li>
<li>Suppression of androgen-driven tumor proliferation and prostate-cancer survival programs</li>
<li>Functional endocrine blockade when paired with castration or GnRH/LHRH therapy</li>
<li>Context-dependent partial agonist behavior or loss of antagonism in resistant AR-mutant or castration-resistant settings</li>
<li>Secondary modulation of downstream stress, MAPK, NF-κB, and related signaling in some preclinical models, usually not the defining clinical mechanism</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral and well absorbed; absolute bioavailability is not defined in the label. It is highly protein bound and the active R-enantiomer has a long elimination half-life of about 1 week, supporting once-daily dosing. Exposure can increase in severe hepatic impairment, and the drug is metabolized hepatically. Bicalutamide can inhibit CYP3A4 and can potentiate coumarin anticoagulant effects.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> The core mechanism is receptor occupancy rather than very high concentration-driven nonspecific cytotoxicity. Some in-vitro pathway effects reported outside AR blockade, especially combination-study MAPK/JNK/NF-κB findings, may reflect model-specific or supra-clinical conditions and should not be treated as the principal translational mechanism.</p>
<p><b>Clinical evidence status:</b> Established approved drug for metastatic prostate cancer in combination with LHRH therapy; not approved in the US as 150 mg monotherapy. Strong historical human evidence exists, but current practice in many settings has shifted toward newer androgen receptor pathway inhibitors with greater potency and better evidence in modern disease states.</p>
<h3>Mechanistic table</h3>
<table>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Androgen receptor signaling</td>
<td>↓ AR transcriptional output</td>
<td>↓ androgen signaling in androgen-responsive tissues</td>
<td>R-G</td>
<td>Blocks ligand-driven AR signaling</td>
<td>Core mechanism and main therapeutic axis. Best supported in prostate cancer.</td>
</tr>
<tr>
<td>2</td>
<td>Androgen-dependent proliferation and survival</td>
<td>↓ proliferation, ↓ tumor support programs</td>
<td>↔ in most non-androgen-dependent tissues</td>
<td>G</td>
<td>Cytostatic endocrine suppression</td>
<td>Effect depends strongly on AR dependence of the tumor.</td>
</tr>
<tr>
<td>3</td>
<td>Combined androgen blockade</td>
<td>↓ residual androgen-axis signaling</td>
<td>Systemic endocrine effects ↑</td>
<td>G</td>
<td>Adds AR blockade to castration or GnRH suppression</td>
<td>Main approved clinical use is with LHRH analog therapy, not as modern stand-alone intensification.</td>
</tr>
<tr>
<td>4</td>
<td>AR antagonist to agonist conversion in resistance</td>
<td>↔ or ↑ AR signaling (context-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Therapeutic escape</td>
<td>In resistant or mutant AR contexts, first-generation antiandrogens can lose antagonism or behave as partial agonists.</td>
</tr>
<tr>
<td>5</td>
<td>MAPK stress signaling</td>
<td>↔ or mixed (model-dependent)</td>
<td>↔</td>
<td>R-G</td>
<td>Secondary signaling modulation</td>
<td>Nestronics lists MEK↑, p-ERK↑, SAPK↑, p-JNK↓ from a combination paper; this is not a robust core bicalutamide mechanism.</td>
</tr>
<tr>
<td>6</td>
<td>NF-κB inflammatory survival axis</td>
<td>↓ (model-dependent)</td>
<td>↔</td>
<td>R-G</td>
<td>May reduce pro-survival signaling in some models</td>
<td>Support is preclinical and often combination-context rather than a defining monotherapy action.</td>
</tr>
<tr>
<td>7</td>
<td>MUC1 and migration-related signaling</td>
<td>↓ migration-associated programs (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Possible anti-migratory effect in selected models</td>
<td>Low-centrality mechanism; evidence is limited and not broadly clinical.</td>
</tr>
<tr>
<td>8</td>
<td>Clinical Translation Constraint</td>
<td>Resistance heterogeneity ↑; efficacy strongest in AR-driven disease</td>
<td>Hepatic toxicity risk, gynecomastia, anticoagulant interaction</td>
<td>G</td>
<td>Limits durability and broad applicability</td>
<td>Important constraints are AR-mutation or CRPC escape, liver monitoring, CYP3A4 and warfarin interaction risk, and the fact that current standard care often favors newer AR inhibitors.</td>
</tr>
</table>
<p>TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr</p>